A Phase III Randomised Double-blind Placebo-controlled Event-driven Study to Assess the Efficacy Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure

Brief description of study

The purpose of this study is to investigate the efficacy, safety and tolerability of baxdrostat in combination with dapagliflozin, compared with placebo and dapagliflozin intreating patient with chronic kidney disease (CKD) and high blood pressure.

Clinical Study Identifier: s25-00230

ClinicalTrials.gov Identifier: NCT06742723

Principal Investigator: David Michael Charytan.

Other Investigators: Sindhuri Prakash-Polet, Michal L Melamed.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies

Brief description of study

Recruitment Status

Contact the research team to learn more about this study.

Recruitment Status

212-263-4432

646-754-7432